The global cancer supportive care drugs market is expected to surpass $17 billion by 2030 due to the increase in cancer cases and the need for supportive care drugs to manage the adverse effects of treatments like chemotherapy. North America holds the largest market share, driven by the rising number of cancer cases and the aging population. The market dynamics are influenced by factors such as the prevalence of cancer, innovation in drug development, regulatory policies, and patient education. Key players in the market include AstraZeneca, Merck Sharp & Dohme, and Pfizer. DelveInsight provides in-depth market insights and forecasts for various cancer types, such as metastatic prostate cancer, HER2-positive breast cancer, and non-small cell lung cancer.